Earnings Summary

Lava Therapeutics Nv’s revenue fell -86.63% since last year same period to $0.35Mn in the Q4 2023. On a quarterly growth basis, Lava Therapeutics Nv has generated 566.04% jump in its revenue since last 3-months.

Lava Therapeutics Nv’s net profit jumped 56.67% since last year same period to $-6.5Mn in the Q4 2023. On a quarterly growth basis, Lava Therapeutics Nv has generated 26.46% jump in its net profits since last 3-months.

Lava Therapeutics Nv’s net profit margin fell -224.07% since last year same period to -1840.8% in the Q4 2023. On a quarterly growth basis, Lava Therapeutics Nv has generated 88.96% jump in its net profit margins since last 3-months.

Lava Therapeutics Nv’s earning per share (EPS) estimates for the current quarter stand at -0.12 - a 0% jump from last quarter’s estimates.

Lava Therapeutics Nv’s earning per share (EPS) estimates for the current year stand at -0.12.

Lava Therapeutics Nv’s earning per share (EPS) jumped 66.67% since last year same period to -0.24 in the Q4 2023. This indicates that the Lava Therapeutics Nv has generated 66.67% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Lava Therapeutics Nv’s return on assets (ROA) stands at -0.22.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Lava Therapeutics Nv’s return on equity (ROE) stands at -0.61.